Pharma & Healthcare
Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Research Report 2025
- Jun 06, 25
- ID: 289807
- Pages: 104
- Figures: 105
- Views: 27
The global market for Paroxysmal Nocturnal Hemoglobinuria Drug was valued at US$ 4039 million in the year 2024 and is projected to reach a revised size of US$ 9393 million by 2031, growing at a CAGR of 13.0% during the forecast period.
North American market for Paroxysmal Nocturnal Hemoglobinuria Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Paroxysmal Nocturnal Hemoglobinuria Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug include Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Drug.
The Paroxysmal Nocturnal Hemoglobinuria Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
CinnaGen Co
Ra Pharmaceuticals Inc
Amgen Inc
Achillion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
NorthStar Rx LLC
Abbott
Par Pharmaceutical
Segment by Type
Eculizumab
Ravulizumab
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Paroxysmal Nocturnal Hemoglobinuria Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
North American market for Paroxysmal Nocturnal Hemoglobinuria Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Paroxysmal Nocturnal Hemoglobinuria Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug include Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paroxysmal Nocturnal Hemoglobinuria Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paroxysmal Nocturnal Hemoglobinuria Drug.
The Paroxysmal Nocturnal Hemoglobinuria Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Paroxysmal Nocturnal Hemoglobinuria Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Apellis Pharmaceuticals
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
CinnaGen Co
Ra Pharmaceuticals Inc
Amgen Inc
Achillion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
BIOCAD
Samsung Bioepis
Amyndas Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
LGM Pharma.
Lannett
NorthStar Rx LLC
Abbott
Par Pharmaceutical
Segment by Type
Eculizumab
Ravulizumab
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Paroxysmal Nocturnal Hemoglobinuria Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Paroxysmal Nocturnal Hemoglobinuria Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview
1.1 Product Definition
1.2 Paroxysmal Nocturnal Hemoglobinuria Drug by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Eculizumab
1.2.3 Ravulizumab
1.2.4 Others
1.3 Paroxysmal Nocturnal Hemoglobinuria Drug by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Estimates and Forecasts
1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2020-2031
1.4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2020-2031
1.4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition by Manufacturers
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Product Type & Application
2.7 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Date of Enter into This Industry
2.8 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation and Trends
2.8.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players Market Share by Revenue
2.8.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Scenario by Region
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2020-2031
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2020-2025
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2026-2031
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020-2031
3.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020-2025
3.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2026-2031
3.4 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.4.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.4.3 North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.5.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.5.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.7.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.7.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2020-2031)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2020-2025)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2026-2031)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2020-2031)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2020-2031)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2020-2025)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2026-2031)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2020-2031)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2020-2031)
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2020-2025)
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2026-2031)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2020-2031)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2020-2031)
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2020-2025)
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2026-2031)
5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2020-2031)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Apellis Pharmaceuticals
6.1.1 Apellis Pharmaceuticals Company Information
6.1.2 Apellis Pharmaceuticals Description and Business Overview
6.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.1.5 Apellis Pharmaceuticals Recent Developments/Updates
6.2 Alexion Pharmaceuticals Inc
6.2.1 Alexion Pharmaceuticals Inc Company Information
6.2.2 Alexion Pharmaceuticals Inc Description and Business Overview
6.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.2.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
6.3 Akari Therapeutics Plc
6.3.1 Akari Therapeutics Plc Company Information
6.3.2 Akari Therapeutics Plc Description and Business Overview
6.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.3.5 Akari Therapeutics Plc Recent Developments/Updates
6.4 CinnaGen Co
6.4.1 CinnaGen Co Company Information
6.4.2 CinnaGen Co Description and Business Overview
6.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.4.5 CinnaGen Co Recent Developments/Updates
6.5 Ra Pharmaceuticals Inc
6.5.1 Ra Pharmaceuticals Inc Company Information
6.5.2 Ra Pharmaceuticals Inc Description and Business Overview
6.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.5.5 Ra Pharmaceuticals Inc Recent Developments/Updates
6.6 Amgen Inc
6.6.1 Amgen Inc Company Information
6.6.2 Amgen Inc Description and Business Overview
6.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.6.5 Amgen Inc Recent Developments/Updates
6.7 Achillion Pharmaceuticals Inc
6.7.1 Achillion Pharmaceuticals Inc Company Information
6.7.2 Achillion Pharmaceuticals Inc Description and Business Overview
6.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.7.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
6.8 Alnylam Pharmaceuticals Inc
6.8.1 Alnylam Pharmaceuticals Inc Company Information
6.8.2 Alnylam Pharmaceuticals Inc Description and Business Overview
6.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.8.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
6.9 F. Hoffmann-La Roche Ltd
6.9.1 F. Hoffmann-La Roche Ltd Company Information
6.9.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.10 Novartis AG
6.10.1 Novartis AG Company Information
6.10.2 Novartis AG Description and Business Overview
6.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.10.5 Novartis AG Recent Developments/Updates
6.11 Regeneron Pharmaceuticals Inc
6.11.1 Regeneron Pharmaceuticals Inc Company Information
6.11.2 Regeneron Pharmaceuticals Inc Description and Business Overview
6.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.11.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
6.12 BIOCAD
6.12.1 BIOCAD Company Information
6.12.2 BIOCAD Description and Business Overview
6.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.12.5 BIOCAD Recent Developments/Updates
6.13 Samsung Bioepis
6.13.1 Samsung Bioepis Company Information
6.13.2 Samsung Bioepis Description and Business Overview
6.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.13.5 Samsung Bioepis Recent Developments/Updates
6.14 Amyndas Pharmaceuticals
6.14.1 Amyndas Pharmaceuticals Company Information
6.14.2 Amyndas Pharmaceuticals Description and Business Overview
6.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.14.5 Amyndas Pharmaceuticals Recent Developments/Updates
6.15 Teva Pharmaceutical Industries Ltd.
6.15.1 Teva Pharmaceutical Industries Ltd. Company Information
6.15.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.16 LGM Pharma.
6.16.1 LGM Pharma. Company Information
6.16.2 LGM Pharma. Description and Business Overview
6.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.16.5 LGM Pharma. Recent Developments/Updates
6.17 Lannett
6.17.1 Lannett Company Information
6.17.2 Lannett Description and Business Overview
6.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.17.5 Lannett Recent Developments/Updates
6.18 NorthStar Rx LLC
6.18.1 NorthStar Rx LLC Company Information
6.18.2 NorthStar Rx LLC Description and Business Overview
6.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.18.5 NorthStar Rx LLC Recent Developments/Updates
6.19 Abbott
6.19.1 Abbott Company Information
6.19.2 Abbott Description and Business Overview
6.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.19.5 Abbott Recent Developments/Updates
6.20 Par Pharmaceutical
6.20.1 Par Pharmaceutical Company Information
6.20.2 Par Pharmaceutical Description and Business Overview
6.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.20.5 Par Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Chain Analysis
7.2 Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paroxysmal Nocturnal Hemoglobinuria Drug Production Mode & Process Analysis
7.4 Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Marketing
7.4.1 Paroxysmal Nocturnal Hemoglobinuria Drug Sales Channels
7.4.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
7.5 Paroxysmal Nocturnal Hemoglobinuria Drug Customer Analysis
8 Paroxysmal Nocturnal Hemoglobinuria Drug Market Dynamics
8.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Trends
8.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
8.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market Challenges
8.4 Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Paroxysmal Nocturnal Hemoglobinuria Drug by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Eculizumab
1.2.3 Ravulizumab
1.2.4 Others
1.3 Paroxysmal Nocturnal Hemoglobinuria Drug by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Estimates and Forecasts
1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2020-2031
1.4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2020-2031
1.4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition by Manufacturers
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Product Type & Application
2.7 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Date of Enter into This Industry
2.8 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation and Trends
2.8.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players Market Share by Revenue
2.8.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Scenario by Region
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2020-2031
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2020-2025
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2026-2031
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020-2031
3.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020-2025
3.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2026-2031
3.4 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.4.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.4.3 North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.5.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.5.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.7.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.7.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2020-2031)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2020-2025)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2026-2031)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2020-2031)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2020-2031)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2020-2025)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2026-2031)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2020-2031)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2020-2031)
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2020-2025)
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2026-2031)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2020-2031)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2020-2031)
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2020-2025)
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2026-2031)
5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2020-2031)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Apellis Pharmaceuticals
6.1.1 Apellis Pharmaceuticals Company Information
6.1.2 Apellis Pharmaceuticals Description and Business Overview
6.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.1.5 Apellis Pharmaceuticals Recent Developments/Updates
6.2 Alexion Pharmaceuticals Inc
6.2.1 Alexion Pharmaceuticals Inc Company Information
6.2.2 Alexion Pharmaceuticals Inc Description and Business Overview
6.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.2.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
6.3 Akari Therapeutics Plc
6.3.1 Akari Therapeutics Plc Company Information
6.3.2 Akari Therapeutics Plc Description and Business Overview
6.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.3.5 Akari Therapeutics Plc Recent Developments/Updates
6.4 CinnaGen Co
6.4.1 CinnaGen Co Company Information
6.4.2 CinnaGen Co Description and Business Overview
6.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.4.5 CinnaGen Co Recent Developments/Updates
6.5 Ra Pharmaceuticals Inc
6.5.1 Ra Pharmaceuticals Inc Company Information
6.5.2 Ra Pharmaceuticals Inc Description and Business Overview
6.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.5.5 Ra Pharmaceuticals Inc Recent Developments/Updates
6.6 Amgen Inc
6.6.1 Amgen Inc Company Information
6.6.2 Amgen Inc Description and Business Overview
6.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.6.5 Amgen Inc Recent Developments/Updates
6.7 Achillion Pharmaceuticals Inc
6.7.1 Achillion Pharmaceuticals Inc Company Information
6.7.2 Achillion Pharmaceuticals Inc Description and Business Overview
6.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.7.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
6.8 Alnylam Pharmaceuticals Inc
6.8.1 Alnylam Pharmaceuticals Inc Company Information
6.8.2 Alnylam Pharmaceuticals Inc Description and Business Overview
6.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.8.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
6.9 F. Hoffmann-La Roche Ltd
6.9.1 F. Hoffmann-La Roche Ltd Company Information
6.9.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.10 Novartis AG
6.10.1 Novartis AG Company Information
6.10.2 Novartis AG Description and Business Overview
6.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.10.5 Novartis AG Recent Developments/Updates
6.11 Regeneron Pharmaceuticals Inc
6.11.1 Regeneron Pharmaceuticals Inc Company Information
6.11.2 Regeneron Pharmaceuticals Inc Description and Business Overview
6.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.11.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
6.12 BIOCAD
6.12.1 BIOCAD Company Information
6.12.2 BIOCAD Description and Business Overview
6.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.12.5 BIOCAD Recent Developments/Updates
6.13 Samsung Bioepis
6.13.1 Samsung Bioepis Company Information
6.13.2 Samsung Bioepis Description and Business Overview
6.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.13.5 Samsung Bioepis Recent Developments/Updates
6.14 Amyndas Pharmaceuticals
6.14.1 Amyndas Pharmaceuticals Company Information
6.14.2 Amyndas Pharmaceuticals Description and Business Overview
6.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.14.5 Amyndas Pharmaceuticals Recent Developments/Updates
6.15 Teva Pharmaceutical Industries Ltd.
6.15.1 Teva Pharmaceutical Industries Ltd. Company Information
6.15.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.16 LGM Pharma.
6.16.1 LGM Pharma. Company Information
6.16.2 LGM Pharma. Description and Business Overview
6.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.16.5 LGM Pharma. Recent Developments/Updates
6.17 Lannett
6.17.1 Lannett Company Information
6.17.2 Lannett Description and Business Overview
6.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.17.5 Lannett Recent Developments/Updates
6.18 NorthStar Rx LLC
6.18.1 NorthStar Rx LLC Company Information
6.18.2 NorthStar Rx LLC Description and Business Overview
6.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.18.5 NorthStar Rx LLC Recent Developments/Updates
6.19 Abbott
6.19.1 Abbott Company Information
6.19.2 Abbott Description and Business Overview
6.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.19.5 Abbott Recent Developments/Updates
6.20 Par Pharmaceutical
6.20.1 Par Pharmaceutical Company Information
6.20.2 Par Pharmaceutical Description and Business Overview
6.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.20.5 Par Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Chain Analysis
7.2 Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paroxysmal Nocturnal Hemoglobinuria Drug Production Mode & Process Analysis
7.4 Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Marketing
7.4.1 Paroxysmal Nocturnal Hemoglobinuria Drug Sales Channels
7.4.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
7.5 Paroxysmal Nocturnal Hemoglobinuria Drug Customer Analysis
8 Paroxysmal Nocturnal Hemoglobinuria Drug Market Dynamics
8.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Trends
8.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
8.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market Challenges
8.4 Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Product Type & Application
Table 12. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2020-2025)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2026-2031)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2020-2025)
Table 53. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2026-2031)
Table 54. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2020-2025)
Table 63. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2026-2031)
Table 64. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2026-2031)
Table 70. Apellis Pharmaceuticals Company Information
Table 71. Apellis Pharmaceuticals Description and Business Overview
Table 72. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 74. Apellis Pharmaceuticals Recent Developments/Updates
Table 75. Alexion Pharmaceuticals Inc Company Information
Table 76. Alexion Pharmaceuticals Inc Description and Business Overview
Table 77. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 79. Alexion Pharmaceuticals Inc Recent Developments/Updates
Table 80. Akari Therapeutics Plc Company Information
Table 81. Akari Therapeutics Plc Description and Business Overview
Table 82. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 84. Akari Therapeutics Plc Recent Developments/Updates
Table 85. CinnaGen Co Company Information
Table 86. CinnaGen Co Description and Business Overview
Table 87. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 89. CinnaGen Co Recent Developments/Updates
Table 90. Ra Pharmaceuticals Inc Company Information
Table 91. Ra Pharmaceuticals Inc Description and Business Overview
Table 92. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 94. Ra Pharmaceuticals Inc Recent Developments/Updates
Table 95. Amgen Inc Company Information
Table 96. Amgen Inc Description and Business Overview
Table 97. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 99. Amgen Inc Recent Developments/Updates
Table 100. Achillion Pharmaceuticals Inc Company Information
Table 101. Achillion Pharmaceuticals Inc Description and Business Overview
Table 102. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 104. Achillion Pharmaceuticals Inc Recent Developments/Updates
Table 105. Alnylam Pharmaceuticals Inc Company Information
Table 106. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 107. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 109. Alnylam Pharmaceuticals Inc Recent Developments/Updates
Table 110. F. Hoffmann-La Roche Ltd Company Information
Table 111. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 112. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 114. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 115. Novartis AG Company Information
Table 116. Novartis AG Description and Business Overview
Table 117. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 119. Novartis AG Recent Developments/Updates
Table 120. Regeneron Pharmaceuticals Inc Company Information
Table 121. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 122. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 124. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 125. BIOCAD Company Information
Table 126. BIOCAD Description and Business Overview
Table 127. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 129. BIOCAD Recent Developments/Updates
Table 130. Samsung Bioepis Company Information
Table 131. Samsung Bioepis Description and Business Overview
Table 132. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 134. Samsung Bioepis Recent Developments/Updates
Table 135. Amyndas Pharmaceuticals Company Information
Table 136. Amyndas Pharmaceuticals Description and Business Overview
Table 137. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 139. Amyndas Pharmaceuticals Recent Developments/Updates
Table 140. Teva Pharmaceutical Industries Ltd. Company Information
Table 141. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 142. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 144. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 145. LGM Pharma. Company Information
Table 146. LGM Pharma. Description and Business Overview
Table 147. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 149. LGM Pharma. Recent Developments/Updates
Table 150. Lannett Company Information
Table 151. Lannett Description and Business Overview
Table 152. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 154. Lannett Recent Developments/Updates
Table 155. NorthStar Rx LLC Company Information
Table 156. NorthStar Rx LLC Description and Business Overview
Table 157. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 159. NorthStar Rx LLC Recent Developments/Updates
Table 160. Abbott Company Information
Table 161. Abbott Description and Business Overview
Table 162. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 164. Abbott Recent Developments/Updates
Table 165. Par Pharmaceutical Company Information
Table 166. Par Pharmaceutical Description and Business Overview
Table 167. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 169. Par Pharmaceutical Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Paroxysmal Nocturnal Hemoglobinuria Drug Distributors List
Table 173. Paroxysmal Nocturnal Hemoglobinuria Drug Customers List
Table 174. Paroxysmal Nocturnal Hemoglobinuria Drug Market Trends
Table 175. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
Table 176. Paroxysmal Nocturnal Hemoglobinuria Drug Market Challenges
Table 177. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Type: 2024 & 2031
Figure 4. Eculizumab Product Picture
Figure 5. Ravulizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Application: 2024 & 2031
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (2020-2031) & (K Units)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (US$/Unit) & (2020-2031)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria Drug Report Years Considered
Figure 17. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Share by Manufacturers in 2024
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players: Market Share by Revenue in Paroxysmal Nocturnal Hemoglobinuria Drug in 2024
Figure 20. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2020-2031)
Figure 35. China Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2020-2031)
Figure 53. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2020-2031)
Figure 54. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Application (2020-2031)
Figure 56. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Application (2020-2031)
Figure 57. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2020-2031)
Figure 58. Paroxysmal Nocturnal Hemoglobinuria Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Paroxysmal Nocturnal Hemoglobinuria Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Product Type & Application
Table 12. Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2025) & (K Units)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2020-2025)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2026-2031) & (K Units)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2026-2031)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 27. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 28. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 32. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 33. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Type (2020-2025)
Table 51. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Type (2026-2031)
Table 52. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2020-2025)
Table 53. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2026-2031)
Table 54. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2020-2025)
Table 59. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2026-2031)
Table 60. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Application (2020-2025)
Table 61. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units) by Application (2026-2031)
Table 62. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2020-2025)
Table 63. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2026-2031)
Table 64. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2020-2025)
Table 69. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2026-2031)
Table 70. Apellis Pharmaceuticals Company Information
Table 71. Apellis Pharmaceuticals Description and Business Overview
Table 72. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 74. Apellis Pharmaceuticals Recent Developments/Updates
Table 75. Alexion Pharmaceuticals Inc Company Information
Table 76. Alexion Pharmaceuticals Inc Description and Business Overview
Table 77. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 79. Alexion Pharmaceuticals Inc Recent Developments/Updates
Table 80. Akari Therapeutics Plc Company Information
Table 81. Akari Therapeutics Plc Description and Business Overview
Table 82. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 84. Akari Therapeutics Plc Recent Developments/Updates
Table 85. CinnaGen Co Company Information
Table 86. CinnaGen Co Description and Business Overview
Table 87. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 89. CinnaGen Co Recent Developments/Updates
Table 90. Ra Pharmaceuticals Inc Company Information
Table 91. Ra Pharmaceuticals Inc Description and Business Overview
Table 92. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 94. Ra Pharmaceuticals Inc Recent Developments/Updates
Table 95. Amgen Inc Company Information
Table 96. Amgen Inc Description and Business Overview
Table 97. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 99. Amgen Inc Recent Developments/Updates
Table 100. Achillion Pharmaceuticals Inc Company Information
Table 101. Achillion Pharmaceuticals Inc Description and Business Overview
Table 102. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 104. Achillion Pharmaceuticals Inc Recent Developments/Updates
Table 105. Alnylam Pharmaceuticals Inc Company Information
Table 106. Alnylam Pharmaceuticals Inc Description and Business Overview
Table 107. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 109. Alnylam Pharmaceuticals Inc Recent Developments/Updates
Table 110. F. Hoffmann-La Roche Ltd Company Information
Table 111. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 112. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 114. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 115. Novartis AG Company Information
Table 116. Novartis AG Description and Business Overview
Table 117. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 119. Novartis AG Recent Developments/Updates
Table 120. Regeneron Pharmaceuticals Inc Company Information
Table 121. Regeneron Pharmaceuticals Inc Description and Business Overview
Table 122. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 124. Regeneron Pharmaceuticals Inc Recent Developments/Updates
Table 125. BIOCAD Company Information
Table 126. BIOCAD Description and Business Overview
Table 127. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 129. BIOCAD Recent Developments/Updates
Table 130. Samsung Bioepis Company Information
Table 131. Samsung Bioepis Description and Business Overview
Table 132. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 134. Samsung Bioepis Recent Developments/Updates
Table 135. Amyndas Pharmaceuticals Company Information
Table 136. Amyndas Pharmaceuticals Description and Business Overview
Table 137. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 139. Amyndas Pharmaceuticals Recent Developments/Updates
Table 140. Teva Pharmaceutical Industries Ltd. Company Information
Table 141. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 142. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 144. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 145. LGM Pharma. Company Information
Table 146. LGM Pharma. Description and Business Overview
Table 147. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 149. LGM Pharma. Recent Developments/Updates
Table 150. Lannett Company Information
Table 151. Lannett Description and Business Overview
Table 152. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 154. Lannett Recent Developments/Updates
Table 155. NorthStar Rx LLC Company Information
Table 156. NorthStar Rx LLC Description and Business Overview
Table 157. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 159. NorthStar Rx LLC Recent Developments/Updates
Table 160. Abbott Company Information
Table 161. Abbott Description and Business Overview
Table 162. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 164. Abbott Recent Developments/Updates
Table 165. Par Pharmaceutical Company Information
Table 166. Par Pharmaceutical Description and Business Overview
Table 167. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product
Table 169. Par Pharmaceutical Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Paroxysmal Nocturnal Hemoglobinuria Drug Distributors List
Table 173. Paroxysmal Nocturnal Hemoglobinuria Drug Customers List
Table 174. Paroxysmal Nocturnal Hemoglobinuria Drug Market Trends
Table 175. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
Table 176. Paroxysmal Nocturnal Hemoglobinuria Drug Market Challenges
Table 177. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Type: 2024 & 2031
Figure 4. Eculizumab Product Picture
Figure 5. Ravulizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Application: 2024 & 2031
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Others
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (2020-2031) & (K Units)
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price (US$/Unit) & (2020-2031)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria Drug Report Years Considered
Figure 17. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Share by Manufacturers in 2024
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players: Market Share by Revenue in Paroxysmal Nocturnal Hemoglobinuria Drug in 2024
Figure 20. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 23. North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 24. United States Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 27. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 28. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2020-2031)
Figure 35. China Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 43. Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2020-2031)
Figure 53. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2020-2031)
Figure 54. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Application (2020-2031)
Figure 56. Global Revenue Market Share of Paroxysmal Nocturnal Hemoglobinuria Drug by Application (2020-2031)
Figure 57. Global Paroxysmal Nocturnal Hemoglobinuria Drug Price (US$/Unit) by Application (2020-2031)
Figure 58. Paroxysmal Nocturnal Hemoglobinuria Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232